DAIICHI SANKYO, INC.

Ona Therapeutics has appointed Dr. Antoine Yver, a veteran with over 35 years of oncology drug development experience, as Chair of its Board of Directors to guide the company's transition to clinical-stage operations.

Marengo Therapeutics has completed the Phase 1b safety run-in of its STARt-002 trial and determined the recommended Phase 2 dose for invikafusp alfa combined with Trodelvy in metastatic breast cancer patients.

Immuto Scientific closed an oversubscribed $8 million Seed 2 financing round led by DYDX to advance its AI-enabled structural surfaceomics platform for drug discovery.

Daiichi Sankyo and Merck received FDA Breakthrough Therapy Designation for raludotatug deruxtecan (R-DXd) in certain ovarian and related cancers after bevacizumab treatment.

Hengrui Medicine's Zemetostat received conditional approval from China's NMPA, becoming the country's first EZH2 inhibitor for treating relapsed or refractory peripheral T-cell lymphoma.

Daiichi Sankyo Europe announced the initiation of development for new oral triple combination tablets containing bempedoic acid, ezetimibe, and different doses of statins (atorvastatin or rosuvastatin) to improve LDL-C management and treatment adherence.

DelveInsight's 2025 pipeline report reveals over 200 companies developing 220+ therapeutic candidates for gastric cancer treatment across all clinical stages.

I-Mab appointed three seasoned biotech executives to key leadership positions, including Dr. Robert Lenz and Ms. Xin Liu to the Board of Directors and Dr. Ken Takeshita to the Scientific Advisory Board.

DelveInsight's 2025 pipeline analysis reveals 25+ companies developing 28+ therapies for gastrointestinal stromal tumors, indicating strong industry investment in this rare cancer space.

Merck and Daiichi Sankyo's ifinatamab deruxtecan received FDA Breakthrough Therapy Designation for extensive-stage small cell lung cancer patients who progressed after platinum-based chemotherapy.